TABLE 2.

Plasmids used in this study

ConstructVector a
LexA-PalApLexA(1-202)+PL
GAD-PalApACTII
GST-PalApGEX-2T
GAD-PacC(341-678)pACTII
GAD-PacC(341-529)pACTII
GAD-PacC(341-529)Y455DpACTII
GAD-PacC(529-678)pACTII
GAD-PacC(529-678)Y662NpACTII
GST-PacC(529-678)pGEX-2T
GST-PacC(169-410)pGEX-2T
His-PacCpD1
His-PacCL340SpD1
His-PacCY455D-Y662NpD1
LexA-SVMYPTLRGLpLexA(1-202)+PL
LexA-SVMAPTLRGLpLexA(1-202)+PL
LexA-SVMYATLRGLpLexA(1-202)+PL
LexA-SVMYPALRGLpLexA(1-202)+PL
LexA-SVMYPTARGLpLexA(1-202)+PL
LexA-SVMNPTLRGLpLexA(1-202)+PL
LexA-Vps32pLexA(1-202)+PL
GAD-AIP1/AlixpACTII
  • a Vectors are pLexA(1-202) + PL (37), pACTII (Clontech), pGEX-2T (Pharmacia), and pD1, a pET19b-derived plasmid that allows the expression of N-terminally His-tagged proteins under the control of a T7 polymerase-dependent promoter (10).